Actavis' U.S. Portfolio To Get A Boost From Alpharma Generic Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
The Iceland-based firm will become a top-five global generic player after acquiring Alpharma's generic business for $810 mil.
You may also be interested in...
FTC Lets King Buy Alpharma Now That Antitrust Problem Is Resolved – But New Embeda Delay Adds Risk To Acquisition
After FTC complaint, King opts to keep Avinza, and let patent-limited competitor go. But a new delay for key Alpharma product could hurt value of acquisition.
FTC Lets King Buy Alpharma Now That Antitrust Problem Is Resolved – But New Embeda Delay Adds Risk To Acquisition
After FTC complaint, King opts to keep Avinza, and let patent-limited competitor go. But a new delay for key Alpharma product could hurt value of acquisition.
Actavis Executive VP-U.S. Commercial And Administration Doug Boothe: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Boothe talks with “The Pink Sheet” DAILY about Actavis’ global and U.S. strategies as the top five generics company looks to keep growing.